CAMP

Over the past six months, CAMP4 Therapeutics Corp. experienced several stock-impacting events: regulatory clearances for CMP-002 were secured in July 2026 from Australia and in September 2026 from Argentina and the UK, enabling the initiation of a Phase 1/2 clinical trial for SYNGAP1-related disorder. The company closed the second tranche of a $100 million private placement in Q2 2026, raising approximately $50.1 million to extend its cash runway through year-end 2028. In May 2026, new preclinical data demonstrated CMP-002 improved seizure threshold and severity in a mouse model of SYNGAP1-related disorder. Analyst sentiment has been generally positive, with a 'Moderate Buy' consensus rating and an average price target of $10.86 as of October 2026, though specific ratings varied, including an 'outperform' from Oppenheimer and a downgrade to 'sell' from Wall Street Zen. In August 2026, CAMP4 reported a quarterly loss of $0.58 per share, missing estimates, with $1.78 million in revenue. Insider trading over 90 days prior to October 10, 2026, showed insiders bought 46,031 shares but sold 593,613 shares.